Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NOR-SWITCH Results ‘Concerning’ In Crohn’s Disease, Says Janssen

Executive Summary

Janssen Biotech says that the NOR-SWITCH study on switching from Remicade to biosimilar infliximab raises “significant questions” over safety and efficacy in patients with Crohn’s disease, and does not support interchangeability.

Advertisement

Related Content

‘Non-Medical Switching’ Claim Riles Europe’s Biosimilars Industry
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel